As our therapies get better and better, and our patients are alive longer and longer, quality of life is becoming an even more important topic going forward.
Dr Stephen Freedland
Dr Stephen Freedland and Professor Axel Merseburger agree that managing prostate cancer requires looking at the whole patient. They discuss steps to keep their patients as fit and healthy as possible, recommend the best lifestyle modifications to maintain or improve cardiovascular and bone health, and talk about how to balance the risks and benefits of active tumour therapy, and when palliative interventions could be needed.
We are shifting the paradigm here to a personalised medicine. We have targeted therapies with many more on their way, so it’s an exciting time.
Dr Stephen Freedland
Dr Stephen Freedland and Professor Axel Merseburger discuss key questions in molecular testing, such as which tests are useful and at what stage it is best to test, and – in light of some recent positive clinical trial results in patients with mCRPC – is there a case for not testing at all? They also talk about what the currently available tests might be missing in those patients who appear to be mutation-negative.
Episode 6: Treatment sequencing in mCRPC: ARPis and beyond
We have great therapies nowadays, and we shouldn’t save them for later. We have to use our best therapies as early as possible.
Dr Bárbara Vieira Lima Aguiar Melão
Dr Stephen Freedland and Dr Bárbara Vieira Lima Aguiar Melão share their expertise on how they choose from the range of available treatments, such as chemotherapy, for their patients who are progressing, why a second androgen receptor pathway inhibitor (ARPi) is not the answer, and when they would do genetic testing to identify patients for poly (ADP-ribose) polymerase (PARP) inhibitor or pembrolizumab therapy.
Episode 5: ASCO GU 2025 round-up: The latest data on emerging therapies
We are seeing that while enzalutamide has benefits, it’s the backbone on which we need to build. It’s an exciting time.
Dr Stephen Freedland
Dr Stephen Freedland and Dr Bárbara Vieira Lima Aguiar Melão discuss their pick of the new data from the 2025 ASCO GU Symposium. Do the latest TALAPRO-2 results herald a new standard of care in first-line treatment of mCRPC? Also under discussion are the potential benefit to patients of adding lutetium-177 prostate-specific membrane antigen or mevrometostat to enzalutamide.
Episode 4: Looking ahead: Treatment questions and emerging targets in mCRPC
We have to be smart to select the correct patients for immunotherapy in general.
Professor Silke Gillessen
Professors Karim Fizazi and Silke Gillessen discuss ongoing research in mCRPC, in-development treatments including immunotherapies, and emerging treatment targets.
Episode 3: Changing treatment approaches for mCRPC: What’s the evidence?
There are many patients who do not receive chemo or who just don’t want to receive chemo. So it’s important to develop drugs for these patients.
Professor Karim Fizazi
Professor Karim Fizazi and Professor Silke Gillessen discuss the evidence for optimal use of both older and more recent treatments for mCRPC, and the role of next-generation sequencing.
Episode 2: Guidelines are for people not diseases: Improving implementation
Guidelines can actually tell us what we should do when data are available, and the level of evidence is actually provided in guidelines, but often there is no evidence.
Professor Karim Fizazi
Professor Karim Fizazi and Dr Elena Castro discuss the available guidelines for the treatment of metastatic castration-resistant prostate cancer (mCRPC), their limitations and what to do when drug approvals outpace the guidelines.
Episode 1: Can progress in mCRPC improve daily clinical practice?
It's great, not only that we have a new treatment, but perhaps even more important that we have a new target, which is prostate-specific membrane antigen (PSMA).
Professor Karim Fizazi
Professor Karim Fizazi and Dr Elena Castro discuss the clinical impact of the latest developments in metastatic castration-resistant prostate cancer (mCRPC) and patients’ perceptions.
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.
